FDA grants Pfizer Breakthrough Therapy designation for its treatment of ROS1-positive non-small cell lung cancer.

Endolysin technology targets unwanted bacteria, including resistant strains

Teva announces that it would pay up to $40 billion in cash and stock to acquire Mylan.

The European Medicines Agency releases findings from marketing authorization application analysis.

The combination of two mAb drugs eradicated a large tumor, but also sparked new toxicity concerns associated with immunotherapies.

GSK notifies CDC and FDA that it is recalling the remaining doses of its 2014–2015 flu vaccine, Flulaval Quadrivalent Thimerosal-free Pre-Filled Syringes, due to decreased potency.

Catalent completes a $52 million expansion program for advanced oral solid manufacturing solutions at its Winchester, KY, facility.

WHO says that results from clinical trials should be reported within 12 months of completion of the study

The acquisition expands Sartorius Stedim Biotech’s service portfolio.

The growing threat and spread of antimicrobial resistance continue to ring alarm bells worldwide.

FDA extends ANDA rule comment period to June 8, 2015 after requests for more time.

The Ph. Eur. contemplates adding specifications for sub-visible particles in eye drops and eye lotions to its monograph.

At the request of FDA, US Marshals seize unapproved prescription drugs from Florida distributor.

India may go to the World Trade Organization if the EU does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences.

Recipharm makes a strategic investment in Synthonics and partners in development of novel compounds.

Efficient freeze-drying processes result in time and energy savings, reduced failure rates, and improved batch consistency.

Pfizer announces that its Phase III trial for Ibrance met its primary endpoint and was ended early due to efficacy based on an assessment by an independent Data Monitoring Committee.

The document serves as guidance for the pharmaceutical industry in data integrity issues and complements existing EU GMP relating to APIs and dosage forms.

This is the first time a single strategy document for both EMA and HMA is presented, reflecting the need for a coordinated approach to address the challenges and opportunities facing the European regulatory system network.

The single-use clarification system eliminates centrigues; harvesting can be performed in one step; and process robustness and predictability are ensured.

CPhI report notes that the Indonesian pharma market is on the brink of a regional manufacturing boom, with market capitalizations and company values rising.

Japanese pharma market evolves towards generics and innovative products, reports CPhI, as CPhI Japan 2015 commences.

Spending on prescription medications reached $373.9 billion in 2014, representing the largest increase in 13 years.

Hydra Biosciences enters into an agreement with Boehringer Ingelheim to research and develop small-molecule TRP inhibitors for renal diseases and disorders.

The European Medicines Agency releases guidelines for addressing and reporting risks associated with medication errors.

The license approval marks another milestone in Aptar Pharma’s ongoing service development to provide large-scale production services to customers.

The pharmaceutical market in Japan is moving towards generic and innovative products, and is expected to hit US$166 billion by 2023.

Agency teams work together to encourage manufacturers to seek approval for previously unapproved drugs.